Century Therapeutics reported net income of -$34.66M for the quarter ended Jun 2026. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | |||||||||||||||||||||||||
| Revenue | 1.06M | 1.40M | 2.22M | 0.52M | 1.72M | 0.10M | 0.15M | 0.27M | 0.85M | 0.77M | 0.79M | 4.17M | 109.16M | ||||||||||||
| Operating items | |||||||||||||||||||||||||
| Research & DevelopmentR&D | 19.55M | 21.80M | 21.20M | 24.49M | 25.90M | 25.59M | 24.90M | 22.73M | 22.79M | 22.30M | 23.42M | 27.22M | 27.23M | 29.38M | 26.58M | 26.86M | 22.53M | 19.70M | 17.11M | 19.59M | |||||
| Selling, General & AdministrativeSG&A | 6.28M | 6.18M | 7.30M | 8.25M | 8.06M | 8.24M | 8.90M | 8.23M | 8.99M | 8.59M | 8.74M | 8.31M | 8.35M | 7.75M | 8.41M | 7.80M | 6.83M | 0.96M | 6.58M | 5.79M | |||||
| Other Operating ExpensesOther Opex | 10.00M | 4.22M | 4.00M | 13.14M | 4.33M | 1.40M | -11.14M | ||||||||||||||||||
| Operating ExpensesOpex | 25.83M | 27.97M | 38.49M | 32.75M | 33.96M | 33.83M | 33.80M | 35.18M | 35.77M | 44.03M | 32.16M | 35.53M | 35.58M | 41.46M | 34.99M | 34.66M | 36.12M | 20.65M | 23.68M | 36.53M | |||||
| Operating IncomeOp. Inc | -25.83M | -27.97M | -37.44M | -31.35M | -31.74M | -33.31M | -32.08M | -35.08M | -35.63M | -43.76M | -31.31M | -34.76M | -34.79M | -37.28M | 74.18M | -34.66M | -36.12M | -20.65M | -23.68M | -36.53M | |||||
| EBIT | -25.83M | -27.97M | -37.44M | -31.35M | -31.74M | -33.31M | -32.08M | -35.08M | -35.63M | -43.76M | -31.31M | -34.76M | -34.79M | -37.28M | 74.18M | -34.66M | -36.12M | -20.65M | -23.68M | -36.53M | |||||
| Non-operating items | |||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.32M | 0.32M | 0.31M | 0.33M | 0.37M | 0.41M | 0.40M | 0.14M | |||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.71M | 1.41M | 2.62M | 3.06M | 3.49M | 3.51M | 3.24M | 3.58M | 3.31M | 2.88M | 2.42M | 2.01M | 1.60M | 1.31M | 2.02M | 1.98M | |||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.18M | -0.18M | 0.25M | 0.01M | -0.02M | 4.44M | -0.19M | -0.19M | 0.01M | -0.01M | 0.01M | -0.01M | 0.25M | 3.38M | -0.04M | 0.11M | 0.10M | 4.42M | 0.02M | -0.01M | |||||
| Non Operating IncomeNon Op. Inc. | 0.38M | 1.01M | 1.66M | 2.02M | 2.74M | 3.50M | 3.50M | 3.25M | 3.57M | 3.56M | 2.99M | 2.38M | 2.12M | 1.70M | 1.41M | 2.04M | 1.98M | ||||||||
| Net income details | |||||||||||||||||||||||||
| EBT | -26.01M | -28.15M | -37.50M | -30.97M | -30.72M | -31.65M | -30.06M | -32.34M | -32.13M | -40.27M | -28.06M | -31.18M | -31.23M | -34.30M | 76.56M | -32.54M | -34.42M | -19.28M | -21.66M | -34.55M | |||||
| Tax ProvisionsTaxes | 0.02M | 0.02M | 0.03M | 0.03M | 1.21M | 0.95M | 0.59M | -0.87M | 0.00M | 0.02M | -0.01M | -26.17M | |||||||||||||
| Profit After TaxPAT | -26.07M | -28.78M | -37.51M | -30.99M | -30.92M | -30.54M | -31.26M | -33.29M | -32.82M | -39.40M | -28.06M | -31.21M | -31.23M | -36.07M | 76.56M | -32.76M | -34.44M | -19.46M | -21.64M | -34.66M | |||||
| Income from Continuing OperationsIncome (Continuing) | -26.01M | -28.15M | -37.51M | -30.99M | -30.75M | -31.68M | -31.26M | -33.29M | -32.72M | -39.40M | -28.06M | -31.21M | -31.23M | -8.13M | 76.56M | -32.54M | -34.42M | -19.28M | -21.66M | -34.55M | |||||
| Consolidated Net IncomeConsol Net Inc. | -26.01M | -28.15M | -37.51M | -30.99M | -30.75M | -31.68M | -31.26M | -33.29M | -32.72M | -39.40M | -28.06M | -31.21M | -31.23M | -8.13M | 76.56M | -32.54M | -34.42M | -19.28M | -21.66M | -34.55M | |||||
| Income towards Parent CompanyParent Net Inc | -26.01M | -28.15M | -37.51M | -30.99M | -30.75M | -31.68M | -31.26M | -33.29M | -32.72M | -39.40M | -28.06M | -31.21M | -31.23M | -8.13M | 76.56M | -32.54M | -34.42M | -19.28M | -21.66M | -34.55M | |||||
| Net Income towards Common StockholdersNet Income | -26.01M | -28.15M | -37.51M | -30.99M | -30.75M | -31.68M | -31.26M | -33.29M | -32.72M | -39.40M | -28.06M | -31.21M | -31.23M | -8.13M | 76.56M | -32.54M | -34.42M | -19.28M | -21.66M | -34.55M | |||||
| Additional items | |||||||||||||||||||||||||
| EPS (Basic) | -0.48 | -0.87 | -0.66 | -0.54 | -0.53 | -0.55 | -0.53 | -0.56 | -0.55 | -0.66 | -0.45 | -0.38 | -0.37 | -0.10 | 0.89 | -0.38 | -0.40 | -0.22 | -0.11 | -0.17 | |||||
| EPS (Diluted) | -0.48 | -0.87 | -0.66 | -0.54 | -0.53 | -0.55 | -0.53 | -0.56 | -0.55 | -0.68 | -0.45 | -0.38 | -0.37 | -0.10 | 0.89 | -0.38 | -0.40 | -0.22 | -0.11 | -0.17 | |||||
| Shares Outstanding | 54.47M | 32.39M | 57.05M | 57.69M | 57.97M | 57.76M | 58.61M | 59.25M | 59.45M | 59.31M | 62.30M | 82.09M | 84.70M | 78.65M | 86.02M | 86.24M | 86.46M | 86.56M | 193.47M | 205.78M | |||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 54.47M | 32.39M | 57.05M | 57.69M | 57.97M | 57.76M | 58.61M | 59.25M | 59.45M | 57.76M | 62.30M | 82.09M | 84.70M | 78.65M | 86.10M | 86.24M | 86.46M | 86.56M | 193.47M | 205.78M | |||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 54.64M | 32.39M | 57.59M | 57.59M | 58.18M | 58.47M | 59.11M | 59.31M | 59.51M | 60.34M | 60.34M | 84.55M | 84.55M | 85.84M | 86.15M | 86.32M | 86.53M | 87.52M | 180.10M | 180.55M | |||||
| EBITDA | -25.83M | -27.97M | -37.44M | -31.35M | -31.74M | -33.31M | -32.08M | -35.08M | -35.63M | -43.76M | -31.31M | -34.76M | -34.79M | -37.28M | 74.18M | -34.66M | -36.12M | -20.65M | -23.68M | -36.53M | |||||
| Interest ExpensesInt Expense | 0.32M | 0.32M | 0.31M | 0.33M | 0.37M | 0.41M | 0.40M | 0.14M | |||||||||||||||||
| Tax Rate | -0.04% | -0.06% | -0.08% | -0.10% | -4.02% | -2.94% | -1.84% | 2.15% | 0.00% | -0.07% | 0.03% | 76.30% |